$SATT
SATIVUS TECH CORP. Stock $satt

$satt Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000168316824001970 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$89.00K	$150.0K	$562.0K
YoY Change	-44.38%	-11.76%	-14.85%
% of Gross Profit
Research & Development	$126.0K	-$48.00K	$253.0K
YoY Change	-45.92%	-126.82%	-62.41%
% of Gross Profit
Depreciation & Amortization	$13.00K	$21.00K	$60.00K
YoY Change	30.0%	950.0%	57.89%
% of Gross Profit
Operating Expenses	$126.0K	$102.0K	$253.0K
YoY Change	-45.92%	-70.77%	-62.41%
Operating Profit	-$215.0K		-$815.0K
YoY Change	-45.29%		-38.86%
Interest Expense	$203.0K	-$152.0K	$228.0K
YoY Change	163.64%	-58.13%	-147.5%
% of Operating Profit
Other Income/Expense, Net	$203.0K		$228.0K
YoY Change	163.64%		-147.5%
Pretax Income	-$12.00K	-$254.0K	-$587.0K
YoY Change	-96.2%	-64.33%	-67.62%
Income Tax
% Of Pretax Income
Net Earnings	$70.00K	-$224.0K	-$324.0K
YoY Change	-137.63%	-64.5%	-82.13%
Net Earnings / Revenue
Basic Earnings Per Share	$0.02		-$0.08
Diluted Earnings Per Share	$0.02	-$0.05	-$0.08
COMMON SHARES
Basic Shares Outstanding	4.216M shares	4.216M shares	4.216M shares
Diluted Shares Outstanding	4.216M shares		4.216M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$579.0K	$813.0K	$813.0K
YoY Change	-58.64%	0.37%	0.37%
Cash & Equivalents	$141.0K	$176.0K	$176.0K
Short-Term Investments	$438.0K	$637.0K	$637.0K
Other Short-Term Assets	$290.0K	$313.0K	$324.0K
YoY Change	286.67%	268.24%	256.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$313.0K
Total Short-Term Assets	$880.0K	$1.137M	$1.137M
YoY Change	-40.58%	26.19%	26.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$358.0K	$256.0K	$271.0K
YoY Change	49.79%	16.89%	8.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$369.0K	$271.0K	$271.0K
YoY Change	39.25%	8.84%	8.84%
TOTAL ASSETS
Total Short-Term Assets	$880.0K	$1.137M	$1.137M
Total Long-Term Assets	$369.0K	$271.0K	$271.0K
Total Assets	$1.249M	$1.408M	$1.408M
YoY Change	-28.47%	22.43%	22.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$90.00K	$46.00K	$46.00K
YoY Change	114.29%	-16.36%	-16.36%
Accrued Expenses	$6.000K	$13.00K	$13.00K
YoY Change	-80.0%	-59.38%	-59.38%
Deferred Revenue
YoY Change
Short-Term Debt	$2.116M	$2.074M	$2.074M
YoY Change	8.4%	-3.31%	-3.31%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.974M	$3.130M	$3.130M
YoY Change	-9.41%	-15.84%	-15.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.974M	$3.130M	$3.130M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.974M	$3.130M	$3.692M
YoY Change	-9.41%	-15.84%	-7.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.86M	-$22.93M
YoY Change	0.3%	1.43%
Common Stock	$20.65M	$20.64M
YoY Change	516150.0%	516000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.208M	-$2.284M	-$2.284M
YoY Change
Total Liabilities & Shareholders Equity	$1.249M	$1.408M	$1.408M
YoY Change	-28.47%	22.43%	22.43%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$70.00K	-$224.0K	-$324.0K
YoY Change	-137.63%	-64.5%	-82.13%
Depreciation, Depletion And Amortization	$13.00K	$21.00K	$60.00K
YoY Change	30.0%	950.0%	57.89%
Cash From Operating Activities	-$116.0K	-$302.0K	-$932.0K
YoY Change	-72.18%	19.37%	-5.48%
INVESTING ACTIVITIES
Capital Expenditures	$113.0K	$31.00K	$79.00K
YoY Change	334.62%	342.86%	-61.65%
Acquisitions
YoY Change
Other Investing Activities	$199.0K	$84.00K	-$642.0K
YoY Change		1580.0%	-4685.71%
Cash From Investing Activities	$86.00K	$53.00K	-$721.0K
YoY Change	-430.77%	-2750.0%	275.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$5.000K	0.000	$1.019M
YoY Change	-100.48%	-100.0%	-9.18%
NET CHANGE
Cash From Operating Activities	-$116.0K	-302.0K	-$932.0K
Cash From Investing Activities	$86.00K	53.00K	-$721.0K
Cash From Financing Activities	-$5.000K	0.000	$1.019M
Net Change In Cash	-$35.00K	-249.0K	-$634.0K
YoY Change	-105.93%	-140.23%	1032.14%
FREE CASH FLOW
Cash From Operating Activities	-$116.0K	-$302.0K	-$932.0K
Capital Expenditures	$113.0K	$31.00K	$79.00K
Free Cash Flow	-$229.0K	-$333.0K	-$1.011M
YoY Change	-48.31%	28.08%	-15.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001661600
CY2022Q4	us-gaap	Deposit Assets DepositAssets		usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Security12g Title Security12gTitle	Common Stock, par value $0.0001
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4215571	shares
CY2023	dei	Auditor Name AuditorName	Elkana Amitai CPA
CY2023	dei	Auditor Location AuditorLocation	Mitzpe Netofa, Israel
CY2023	dei	Auditor Firm AuditorFirmId	6816
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	810000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	637000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	11000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	313000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	85000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1137000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	901000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	256000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	219000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	271000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	249000	usd
CY2023Q4	us-gaap	Assets Assets	1408000	usd
CY2022Q4	us-gaap	Assets Assets	1150000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	46000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	55000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	114000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2074000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2031000	usd
CY2023Q4	satt	Fair Value Of Convertible Component In Convertible Loans FairValueOfConvertibleComponentInConvertibleLoans	885000	usd
CY2022Q4	satt	Fair Value Of Convertible Component In Convertible Loans FairValueOfConvertibleComponentInConvertibleLoans	1327000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	112000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	160000	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	13000	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	32000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3130000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3719000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20640000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	19756000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22928000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22604000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2284000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2844000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	562000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	275000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1722000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2569000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1408000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1150000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	253000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	673000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	562000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	660000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-815000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1333000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	228000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-480000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-587000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1813000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-263000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-286000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-324000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1527000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4215571	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4215571	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4194443	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4194443	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2569000	usd
CY2023	satt	Stock Issued During Period Value Transactions With Noncontrolling Parties StockIssuedDuringPeriodValueTransactionsWithNoncontrollingParties	1274000	usd
CY2023	satt	Share Based Compensation To Employees And Nonemployee ShareBasedCompensationToEmployeesAndNonemployee	100000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	74000	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	-14000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-587000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1722000	usd
CY2022	satt	Stock Issued During Period Value Transactions With Noncontrolling Parties StockIssuedDuringPeriodValueTransactionsWithNoncontrollingParties	1308000	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	211000	usd
CY2022	satt	Share Based Compensation To Employees And Nonemployee ShareBasedCompensationToEmployeesAndNonemployee	374000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	133000	usd
CY2022	satt	Issuance Of Shares In Respect Of Converted Safe In Subsidiary IssuanceOfSharesInRespectOfConvertedSafeInSubsidiary	12000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1813000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2569000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-587000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1813000	usd
CY2023	us-gaap	Depreciation Depreciation	60000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	156000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	267000	usd
CY2023	satt	Financial Expenses Related To Convertible Loans Warrants And Leases FinancialExpensesRelatedToConvertibleLoansWarrantsAndLeases	165000	usd
CY2022	satt	Financial Expenses Related To Convertible Loans Warrants And Leases FinancialExpensesRelatedToConvertibleLoansWarrantsAndLeases	320000	usd
CY2023	satt	Change In Fair Value Of Convertible Component In Convertible Loans ChangeInFairValueOfConvertibleComponentInConvertibleLoans	-441000	usd
CY2022	satt	Change In Fair Value Of Convertible Component In Convertible Loans ChangeInFairValueOfConvertibleComponentInConvertibleLoans	117000	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	228000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	8000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-9000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	43000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-48000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	50000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-932000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-986000	usd
CY2023	satt	Decrease Increase In Restricted Cash DecreaseIncreaseInRestrictedCash	5000	usd
CY2022	satt	Decrease Increase In Restricted Cash DecreaseIncreaseInRestrictedCash	-14000	usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	637000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	79000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	206000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-721000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-192000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	114000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	14000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	22000	usd
CY2023	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	-114000	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1273000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1308000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	126000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	278000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1019000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1122000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-634000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-56000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	810000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	866000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	810000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	126000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	175000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22928000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-932000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zN6amV7krgN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zhH5ogYYh9M7">Use of estimates</span>:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zPdruPTJemud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_zfVoluDf478f">Concentration of credit risks</span>:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	156000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	267000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4215571	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4215571	shares
CY2022	satt	Warrants Granted WarrantsGranted	0	shares
CY2022	satt	Warrrants Granted Weighted Average Exercise Price WarrrantsGrantedWeightedAverageExercisePrice	0
CY2022	satt	Warrants Forfeited WarrantsForfeited	13750	shares
CY2022	satt	Warrrants Forfeited Weighted Average Exercise Price WarrrantsForfeitedWeightedAverageExercisePrice	2
CY2022	satt	Warrants Cancelled WarrantsCancelled	66000	shares
CY2022	satt	Warrrants Cancelled Weighted Average Exercise Price WarrrantsCancelledWeightedAverageExercisePrice	1.5
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	119000	shares
CY2023Q4	satt	Class Of Warrant Or Right Outstanding And Exercisable ClassOfWarrantOrRightOutstandingAndExercisable	119000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	195000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	45000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.00
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	80000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.10
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	160000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.05
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	160000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	160000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	160000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	196000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	370000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	30000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	536000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	5000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	531000	shares
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1686000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1686000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1686000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8663000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	228000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-480000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-001970-index-headers.html	Edgar Link	pending
0001683168-24-001970-index.html	Edgar Link	pending
0001683168-24-001970.txt	Edgar Link	pending
0001683168-24-001970-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sativus_ex3101.htm	Edgar Link	pending
sativus_ex3102.htm	Edgar Link	pending
sativus_ex3201.htm	Edgar Link	pending
sativus_ex3202.htm	Edgar Link	pending
sativus_i10k-123123.htm	Edgar Link	pending
satt-20231231.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
satt-20231231_lab.xml	Edgar Link	unprocessable
satt-20231231_def.xml	Edgar Link	unprocessable
satt-20231231_pre.xml	Edgar Link	unprocessable
sativus_i10k-123123_htm.xml	Edgar Link	completed
satt-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SATT
SATIVUS TECH CORP. Stock $satt

2024 Q1 Form 10-K Financial Statement

#000168316824001970 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SATT SATIVUS TECH CORP. Stock $satt

2024 Q1 Form 10-K Financial Statement

#000168316824001970 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SATT
SATIVUS TECH CORP. Stock $satt